Halozyme Therapeutics delivered a notably positive second quarter, as evidenced by the strong market reaction and management’s attribution of outperformance to surging royalty revenue and a wave of new collaboration agreements. CEO Helen Torley highlighted that the ENHANZE platform, now underpinning revenue from six different drugs, enabled a record 50% year-over-year royalty growth. The quarter also benefited from sizable milestone payments tied to newly signed licensing deals, with Torley emph

On July 20, Halozyme Therapeutics, Inc. (NASDAQ:HALO) and Incyte Corporation (NASDAQ:INCY) announced a global collaboration and licensing deal to develop a subcutaneous formulation of Incyte’s INCA033989. The first-in-class monoclonal antibody targets mutant calreticulin (mutCALR)-expressing myeloproliferative neoplasms. By utilizing Halozyme’s proprietary ENHANZE drug delivery technology, INCY aims to create a more convenient dosing regimen for patients. […]

Revenue jumped 48% to $481 million on record royalty growth.

Halozyme Therapeutics (HALO) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Here is how Halozyme Therapeutics (HALO) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.

Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) announced better-than-expected revenue in Q2 CY2026, with sales up 47.7% year on year to $481 million. The company’s full-year revenue guidance of $1.87 billion at the midpoint came in 5.9% above analysts’ estimates. Its non-GAAP profit of $2.28 per share was 25.5% above analysts’ consensus estimates.

Shares of biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) jumped 18.1% in the afternoon session after the company reported strong second-quarter earnings that surpassed analyst expectations and raised its full-year financial guidance.

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

In early August 2026, Halozyme Therapeutics, Inc. reported record second‑quarter results, with revenue rising to US$481 million and net income to US$229.91 million, and raised its full‑year 2026 revenue guidance to a range of US$1.84 billion to US$1.91 billion. The company also accelerated capital returns by completing US$750 million of share repurchases under a 2024 authorization and buying an additional US$175.01 million of stock under a new 2026 program, while signing five new...

Halozyme earnings beat and guidance hike reshape the story Halozyme Therapeutics (HALO) just put fresh numbers on the table, reporting second quarter 2026 results, raising full year revenue guidance and updating progress on its share repurchase programs. For the quarter ended June 30, 2026, revenue was reported at US$481 million compared with US$325.72 million for the same period a year earlier. Net income for the quarter was US$229.91 million compared with US$165.16 million a year ago. Basic...

Halozyme's ENHANZE platform drives a 48% revenue surge, with new partnerships and Hypercon progress fueling a second growth engine.

Stock Market Today: The major indexes close with gains across the board. A medical testing stock soars 20%.

Halozyme stock rocketed to a record high Friday as its newer Enhanze-tied products start driving incremental growth.

Natera and Halozyme Therapeutics saw gains above 15%, led by bullish Wall Street commentary after better-than-expected second-quarter results.

Moby summary of Halozyme Therapeutics, Inc.'s Q2 2026 earnings call

Halozyme Therapeutics (NASDAQ:HALO) reported record second-quarter revenue and raised its full-year outlook, citing growth in royalty income from its ENHANZE drug-delivery platform, contributions from newer product launches and revenue from newly signed collaboration agreements. Total revenue rose

Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +25.28% and +17.44%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 47.7% year on year to $481 million. The company’s full-year revenue guidance of $1.87 billion at the midpoint came in 5.9% above analysts’ estimates. Its non-GAAP profit of $2.28 per share was 25.5% above analysts’ consensus estimates.

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.

This medical technology name has a patented method of drug delivery. Halozyme stock recently hit a record high with earnings due out soon.

Halozyme Therapeutics is at a new high on Friday with earnings due on Aug. 6. Philip Morris International and KeyCorp are also at highs.

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Halozyme Therapeutics recently entered a global partnership and licence agreement with Incyte to apply its Enhanze drug delivery technology to additional subcutaneous formulations of INCA033989, a monoclonal antibody targeting mutant calreticulin in myeloproliferative neoplasms. This collaboration highlights how Halozyme can plug its Enhanze platform into emerging precision oncology assets, potentially broadening future royalty-bearing indications in blood cancers. We’ll now examine how this...

The companies aim to enable simplified dosing and delivery methods for patients receiving treatment for MPNs.

Halozyme Therapeutics (NASDAQ:HALO) has entered into a global collaboration and license agreement with Incyte (NASDAQ:INCY) to support the development of subcutaneous formulations of INCA033989, expanding the use of its ENHANZE® drug delivery technology into another partnered program. Key Investor TakeawaysHalozyme signed a global collaboration and license agreement with Incyte centered on ENHANZE® drug delivery technology.

Halozyme Therapeutics Inc. (NASDAQ:HALO) is one of the 8 Most Undervalued Growth Stocks to Buy for the Next 10 Years. On June 16, H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Halozyme Therapeutics Inc. (NASDAQ:HALO) and assigned a target price of $95. The stock’s potential has been noticed by market participants, as evident […]

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.